Volume 3.31 | Aug 7

LABORATORY RESEARCH

Scl Represses Cardiomyogenesis in Prospective Hemogenic Endothelium and Endocardium
Researchers showed that the transcription factor Scl/Tal1 is essential for both establishing the hematopoietic transcriptional program in the hemogenic endothelium and preventing its misspecification to a cardiomyogenic fate. [Cell] Abstract | Press Release

Targeting Tetramer-Forming GABPβ Isoforms Impairs Self-Renewal of Hematopoietic and Leukemic Stem Cells
Scientists demonstrated that GABPβ1L/β2 deficiency specifically impairs hematopoietic stem cell (HSC) quiescence and survival, with little impact on cell cycle or apoptosis in differentiated blood cells. They also showed targeting GABPβ1L/β2 also impairs leukemia stem cell self-renewal in p210^BCR-ABL-induced chronic myelogenous leukemia (CML) and exhibits synergistic effects with tyrosine kinase inhibitor imatinib therapy in inhibiting CML propagation. [Cell Stem Cell] Abstract

Activated G_s Signaling in Osteoblastic Cells Alters the Hematopoietic Stem Cell Niche in Mice
Researchers suggest that long-term activation of G_s signaling in osteoblastic lineage cells leads to contextual changes in the bone marrow niche that adversely affect hematopoietic stem cell maintenance and blood homeostasis. [Blood] Abstract

Dicer Is Selectively Important for the Earliest Stages of Erythroid Development
By using Dicer inactivation, researchers showed that the microRNA complex is not only essential for hematopoietic stem cell maintenance, but is specifically required for their erythroid programming and subsequent generation of committed erythroid progenitors. [Blood] Abstract

miR-433 Is Aberrantly Expressed in Myeloproliferative Neoplasms and Suppresses Hematopoietic Cell Growth and Differentiation
Despite its upregulation in myeloproliferative neoplasms CD34+ and during normal erythropoiesis, both overexpression and knockdown studies suggest that miR-433 negatively regulates CD34+ proliferation and differentiation ex vivo. Its novel target GBP2 is downregulated during normal erythropoiesis and regulates proliferation and erythroid differentiation in TF-1 cells, indicating that miR-433 negatively regulates hematopoietic cell proliferation and erythropoiesis by directly targeting GBP2. [Leukemia] Abstract

Anti-Leukemic Activity of Nuclear Export Inhibitors that Spare Normal Hematopoietic Cells
Scientists report on the structural analysis and anti-leukemic activity of a new generation of small-molecule inhibitors of chromosome region maintenance 1 protein. [Leukemia] Abstract

High-efficiency Transduction of Rhesus Hematopoietic Repopulating Cells by a Modified HIV1-based Lentiviral Vector
To evaluate whether chimeric human immunodeficiency virus type 1 (χHIV) vectors could efficiently transduce rhesus hematopoietic repopulating cells, researchers performed a competitive repopulation assay in rhesus macaques, in which half of the CD34⁺ cells were transduced with standard simian immunodeficiency virus vectors and the other half with χHIV vectors. [Mol Ther] Abstract

Chemoselection of Allogeneic HSC after Murine Neonatal Transplantation Without Myeloablation or Post-Transplant Immunosuppression
The feasibility of allogeneic transplantation, without myeloablation or post-transplant immunosuppression, was tested using in vivo chemoselection of allogeneic hematopoietic stem cells (HSCs) after transduction with a novel tricistronic lentiviral vector. [Mol Ther] Abstract

BMK1 Is Involved in the Regulation of p53 through Disrupting the PML-MDM2 Interaction
Results not only suggest that big MAP kinase 1 (BMK1) activity has a role in suppressing p53 by blocking the interaction between promyelocytic leukemia protein (PML) and MDM2, but also implicate that pharmacological BMK1 inhibitor should significantly enhance the anticancer capacity of doxorubicin-based chemotherapy. [Oncogene] Abstract

CLINICAL RESEARCH

Reversible Skeletal Disease and High Fluoride Serum Levels in Hematologic Patients Receiving Voriconazole
Investigators found that serum fluoride levels were elevated on average five-fold above normal levels in hematological patients receiving voriconazole. Clinically relevant skeletal disease was associated with renal insufficiency and above ten-fold elevated fluoride levels, and was reversible upon termination of voriconazole treatment. [Blood] Abstract

Phase I Study of the Aurora B Kinase Inhibitor Barasertib to Assess the Pharmacokinetics, Metabolism and Excretion in Patients with Acute Myeloid Leukemia
The pharmacokinetic, metabolic and excretion profiles of barasertib and barasertib-hQPA were characterized in this open-label Phase I study. [Cancer Chemother Pharmacol] Abstract

Acetylon Pharmaceuticals Initiates New Phase Ib Clinical Trial of Rocilinostat (ACY-1215) in Combination with Celgene’s Revlimid® (Lenalidomide) and Dexamethasone for Patients with Multiple Myeloma
Acetylon Pharmaceuticals announced it has initiated patient enrollment in a new Phase Ib clinical trial of rocilinostat in combination with Revlimid® and dexamethasone for the treatment of relapsed and relapsed/refractory multiple myeloma. [Acetylon Pharmaceuticals, Inc.] Press Release

University Hospitals Case Medical Center to Study Stem Cell Therapy for Stroke Treatment
A new national study looking at the safety and effectiveness of new medication developed from adult stem cells for the treatment of ischemic stroke has opened at University Hospitals Case Medical Center. [PR Newswire Association LLC.] Press Release

Life of Cancer Patient Suffering from Bone Marrow Failure Saved following Treatment with Pluristem’s PLX Cells
Pluristem Therapeutics, Inc. announced that the life of a patient suffering from bone marrow failure in which there was a dangerous reduction in the number of red blood cells, white blood cells, and platelets has been saved using Placental eXpanded (PLX) cells. [Pluristem Therapeutics, Inc.] Press Release

CPRIT’s Governing Board Ratifies $114 Million in New Cancer Awards
The Cancer Prevention and Research Institute of Texas (CPRIT) announced funding of more than $114 million to support a variety of cancer-fighting efforts in Texas. Highlights among the funded projects include two Phase II clinical trials studying interventions in breast cancer and acute myelogenous leukemia. [Cancer Prevention Research Institute of Texas] Press Release

National Institutes of Health (United States)

Food and Drug Administration (United States)
 
Center for Biologics Evaluation and Research (United States)
 
European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Hibernation of Hematopoietic Stem Cells in Bone Marrow Niche
September 5, 2012
Edinburgh, Scotland

Visit our events page to see a complete list of events in the hematopoietic community.

Quality Control Operations Coordinator (STEMCELL Technologies, Inc.)

Research Technologist – Media Development (STEMCELL Technologies, Inc.)

Research Technologist – Research and Development (STEMCELL Technologies, Inc.)

Scientific Communications and Publishing Coordinator (STEMCELL Technologies, Inc.)

Scientist – Mesenchymal Cell Research (STEMCELL Technologies, Inc.)

Postdoctoral Position – Stem Cell Biology and Developmental Hematopoiesis (Mount Sinai School of Medicine)

Postdoctoral Positions – Stem Cells and Immunology (University of Connecticut)

Postdoctoral Position – Stem Cells (Children’s Hospital of Chicago Research Center)

Postdoctoral Position – Leukemia Stem Cells/Acute Myeloid Leukemia (Lund University)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!